HTuO Biosciences develops novel small molecule therapeutics targeting challenging protein-protein interactions in oncology and immunology. The company utilizes proprietary structure-based drug design platforms to create highly selective and potent drug candidates. This approach aims to deliver first-in-class treatments for diseases with high unmet medical need.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional computer-assisted drug design (CADD) methods often fail to provide sufficiently accurate simulations of drug behavior at the protein scale, leading to suboptimal drug candidates and increased failure rates in drug development. The approximations used in underlying force fields introduce errors that limit the reliability of predictions.
Solution
HTuO Biosciences develops high-accuracy molecular simulation technology to improve the prediction of drug behavior by minimizing errors in protein-scale simulations. Their physics-based approach addresses the root causes of inaccuracies in CADD, providing a more detailed understanding of molecular interactions. By introducing high accuracy into modeling, HTuO enables data-driven predictions of optimal drug designs, ultimately reducing drug failures and increasing the efficacy of new therapeutics. The technology aims to streamline the drug discovery process by delivering insightful information to help design better drugs.
Target Audience
HTuO's primary target audience includes pharmaceutical companies and research institutions involved in drug discovery and development.
Features
- Advanced molecular simulation technology based on physics.
- Minimization of errors in protein-scale simulations.
- High-accuracy modeling for data-driven predictions.